CorMedix Inc. (CRMD) and DBV Technologies S.A. (NASDAQ:DBVT) Contrasting side by side

Since CorMedix Inc. (NYSEAMERICAN:CRMD) and DBV Technologies S.A. (NASDAQ:DBVT) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CorMedix Inc. 6 0.00 25.14M -1.18 0.00
DBV Technologies S.A. 7 0.00 28.07M -3.27 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 shows us CorMedix Inc. and DBV Technologies S.A.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
CorMedix Inc. 430,479,452.05% 0% -145.2%
DBV Technologies S.A. 377,284,946.24% 0% 0%

Analyst Recommendations

The table given features the ratings and recommendations for CorMedix Inc. and DBV Technologies S.A.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CorMedix Inc. 0 0 0 0.00
DBV Technologies S.A. 0 0 1 3.00

Competitively the average price target of DBV Technologies S.A. is $14, which is potential 81.58% upside.

Insider & Institutional Ownership

Roughly 16.8% of CorMedix Inc. shares are held by institutional investors while 46.27% of DBV Technologies S.A. are owned by institutional investors. 0.8% are CorMedix Inc.’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CorMedix Inc. 8.39% 6.25% 22.35% 3.09% 176.86% 50.23%
DBV Technologies S.A. -6.24% 9.23% -0.94% 41.55% -46.5% 47.51%

For the past year CorMedix Inc. was more bullish than DBV Technologies S.A.


CorMedix Inc. beats on 5 of the 9 factors DBV Technologies S.A.

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Bridgewater, New Jersey.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage product development programs include treatments for Crohn’s disease and respiratory syncytial virus. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.